WHO ICTRP trial
Phase II exploratory study on clinical effects and biomarkers of bevacizumab…
ChiCTR2400090725 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2400090725 |
|---|---|
| Public title | Phase II exploratory study on clinical effects and biomarkers of bevacizumab combined with concurrent chemoradiotherapy in the treatment of local advanced cervical cancer |
| Scientific title | Phase II exploratory study on clinical effects and biomarkers of bevacizumab combined with concurrent chemoradiotherapy in the treatment of local advanced cervical cancer |
| Primary sponsor | Fuyang City Cancer Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 2 |
| Countries | China |
| Conditions | cervical cancer |
| Interventions | experimental group:Cisplatin 40 mg/m2 Iv Day 1, qw for 5 weeks; Bevacizumab 10 mg/kg a Day 1, q2w, a total of 3 courses Radiotherapy: Pelvic radiotherapy 45Gy, 25 times, 5 times/week; After loading treatment 40Gy, 1-2 LDR or 30Gy5 HDR |
| Registration date | Oct 12, 2024 |
| Target size | experimental group:38 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: